Clinical trial
A Phase 1/2 Open-Label Study of the Safety and Clinical Activity of Gene Therapy for Canavan Disease Through Administration of an Adeno-Associated Virus (AAV) Serotype 9-Based Recombinant Vector Encoding the Human ASPA Gene
NCT04998396 is registered in ClinicalTrials.gov with Aspa Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Open-Label Study of the Safety and Clinical Activity of Gene Therapy for Canavan Disease Through Administration of an Adeno-Associated Virus (AAV) Serotype 9-Based Recombinant Vector Encoding the Human ASPA Gene
- Lead sponsor
- Aspa Therapeutics
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- September 8, 2021
- Completion date
- October 8, 2032
- Enrollment
- 26 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.